HBcrAg在慢性乙型肝炎中研究进展  

Research Progress of HBcrAg in Chronic Hepatitis B

作　　者：党便利 孙永涛[1] 康文臻[1] DANG Bian-li;SUN Yong-tao;KANG Wen-zhen(Infectious Disease Diagnosis and Treatment Center of the PLA,Tangdu Hospital,Fourth Military Medical University,Xi'an 710038,Shaanxi,China)

机构地区：[1]第四军医大学唐都医院全军感染病诊疗中心,陕西西安710038

出　　处：《医学信息》2020年第17期23-26,共4页Journal of Medical Information

基　　金：“十三五”科技重大专项(编号:2017ZX10202203-008-003、2017ZX10202101-003-007、2017ZX10202101-004-005、2017ZX10202102-002-001);陕西省重点研发计划(编号:S2018-YF-YBSF-0852)。

摘　　要：肝内共价闭合环状DNA(cccDNA)的存在导致乙型肝炎病毒(HBV)不能从感染的肝细胞中完全清除。乙型肝炎核心相关抗原(HBcrAg)作为非侵入性肝活检的替代物,与血清HBV DNA和肝内cccDNA相关,在慢性乙型肝炎(CHB)中具有重要作用。在血清HBV DNA或HBsAg不可检测临床病例中,仍可以检测到HBcrAg,且HBcrAg水平与CHB患者的预后显著相关。HBcrAg可预测自发或由治疗引起的乙肝炎e抗原(HBeAg)血清学转换、核苷类似物停药后的持续应答、潜在HBV再激活以及肝细胞癌进展或复发的风险。本文就HBcrAg的病毒学特点及其在CHB患者中的临床应用作一综述。The presence of covalently closed circular DNA(cccDNA)in the liver prevents the hepatitis B virus(HBV)from being completely eliminated from infected liver cells.Hepatitis B core-associated antigen(HBcrAg),as a non-invasive liver biopsy alternative,is related to serum HBV DNA and intrahepatic cccDNA,and plays an important role in chronic hepatitis B(CHB).In clinical cases where serum HBV DNA or HBsAg is not detectable,HBcrAg can still be detected,and HBcrAg level is significantly related to the prognosis of CHB patients.HBcrAg can predict spontaneous or treatment-induced hepatitis B e antigen(HBeAg)seroconversion,sustained response after discontinuation of nucleoside analogs,potential HBV reactivation,and the risk of hepatocellular carcinoma progression or recurrence.This article reviews the virological characteristics of HBcrAg and its clinical application in CHB patients.

关 键 词：乙型肝炎核心相关抗原 共价闭合环状DNA 乙型肝炎病毒 慢性乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]